PMID- 29280480 OWN - NLM STAT- MEDLINE DCOM- 20190604 LR - 20190604 IS - 1097-0290 (Electronic) IS - 0006-3592 (Linking) VI - 115 IP - 5 DP - 2018 May TI - Identification of process conditions influencing protein aggregation in Chinese hamster ovary cell culture. PG - 1173-1185 LID - 10.1002/bit.26534 [doi] AB - Protein aggregation of monoclonal antibodies (mAbs) is a common phenomenon associated with the production of these biopharmaceuticals. These aggregates can lead to adverse side effects in patients upon administration, thus expensive downstream processing steps to remove the higher molecular weight species are inevitable. A preferable approach is to reduce the level of aggregation during bioprocessing by a careful adjustment of critical process parameters. Recently, new analytical methods enabled characterization of mAb aggregation during bioprocessing of mammalian cells. Furthermore, rapid and efficient bioprocess optimization has been performed using design of experiments (DoE) strategies. In this work, we describe a DoE-based approach for the analysis of process parameters and cell culture additives influencing protein aggregation in Chinese hamster ovary (CHO) cell cultures. Important bioprocess variables influencing the aggregation of mAb and host cell proteins were identified in initial screening experiments. Response surface modeling was further applied in order to find optimal conditions for the reduction of protein aggregation during cell culture. It turned out that a temperature-shift to 31 degrees C, osmolality above 420 mOsm/kg, agitation at 100 rpm and 0.04% (w/v) antifoam significantly reduced the level of aggregates without substantial detrimental effects on cell culture performance in our model system. Finally, the aggregation reducing conditions were verified and applied to another production system using a different bioprocess medium and another CHO cell line producing another mAb. Our results show that protein aggregation can be controlled during cell culture and helps to improve bioprocessing of mAbs, by giving insights into the protein aggregation at its origin in mammalian cell culture. CI - (c) 2017 Wiley Periodicals, Inc. FAU - Paul, Albert J AU - Paul AJ AUID- ORCID: 0000-0003-3684-7329 AD - Institute of Applied Biotechnology, Biberach University of Applied Sciences, Biberach, Germany. FAU - Handrick, Rene AU - Handrick R AD - Institute of Applied Biotechnology, Biberach University of Applied Sciences, Biberach, Germany. FAU - Ebert, Sybille AU - Ebert S AD - Institute of Applied Biotechnology, Biberach University of Applied Sciences, Biberach, Germany. FAU - Hesse, Friedemann AU - Hesse F AD - Institute of Applied Biotechnology, Biberach University of Applied Sciences, Biberach, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180122 PL - United States TA - Biotechnol Bioeng JT - Biotechnology and bioengineering JID - 7502021 RN - 0 (Antibodies, Monoclonal) RN - 0 (Culture Media) RN - 0 (Protein Aggregates) RN - 0 (Recombinant Proteins) SB - IM MH - Animals MH - Antibodies, Monoclonal/chemistry/metabolism MH - CHO Cells MH - Cell Culture Techniques/*methods MH - Cricetulus MH - Culture Media/chemistry MH - Humans MH - *Protein Aggregates MH - *Protein Denaturation MH - *Protein Multimerization MH - Recombinant Proteins/*chemistry/*metabolism MH - Temperature OTO - NOTNLM OT - CHO cells OT - bioprocess engineering OT - monoclonal antibodies OT - protein aggregation EDAT- 2017/12/28 06:00 MHDA- 2019/06/05 06:00 CRDT- 2017/12/28 06:00 PHST- 2017/07/26 00:00 [received] PHST- 2017/11/16 00:00 [revised] PHST- 2017/12/20 00:00 [accepted] PHST- 2017/12/28 06:00 [pubmed] PHST- 2019/06/05 06:00 [medline] PHST- 2017/12/28 06:00 [entrez] AID - 10.1002/bit.26534 [doi] PST - ppublish SO - Biotechnol Bioeng. 2018 May;115(5):1173-1185. doi: 10.1002/bit.26534. Epub 2018 Jan 22.